Expert Interview
Digging into the the results from the Phase 3 RATIONALE-306 study, regarding BeiGene's Tislelizumab plus chemotherapy as first-line treatment for Esophageal Squamous Cell Carcinoma (ESCC)
Ticker(s): BGNEInstitution: Mayo Clinic
- Oncologist at the Mayo Clinic with special interest in neuroendocrine tumors and gastrointestinal malignancies.
- Currently manages patients with colon cancer, esophageal cancer, gallbladder cancer, liver cancer, neuroendocrine tumors, pancreatic cancer, rectal cancer, small bowel cancer, stomach cancer.
- Active in research that focuses on investigating novel treatments including targeted therapies, immunotherapy, and other agents for neuroendocrine and gastrointestinal cancers.
Roughly how many patients do you currently manage with ESCC?
Added By: chanell_adminWhat are your overall thoughts on the data from Phase 3 RATIONALE-306 study, regarding Tislelizumab?
Added By: chanell_adminCould you talk a little bit about your professional background and give us some details about your clinical practice?In terms of the standard of care currently, how do you manage the disease and treat patients?
Are there specific FDA approvals for PD-1 or PD-L1 agents in this indication?For the first line, is the approval sufficient to utilize it first line or are there other criteria?
How do you view the opportunity for tislelizumab in the ESCC market?
Is the TAP scoring different from the CPS scoring?
How confident are you that tislelizumab showed benefit in the subgroup of less than 10%?
Would tislelizumab be the preference over existing options for patients with PD-L1 less than 10% but above 1%?
How do you view the side effect profile for tislelizumab?Were there any important findings in the subgroup analyses?
Does the efficacy in the less than 10% PD-L1 group suggest tislelizumab might be a better PD-1 antibody compared to others?
On a scale of 1 to 10, how would you rate your excitement about tislelizumab for ESCC?
Do you think the efficacy in the less than 10% PD-L1 group will have broad appeal amongst your colleagues?
Do you think the data from the RATIONALE-306 trial is enough for tislelizumab to get FDA approval?
Added By: slingshot_insightsWere there any other thoughts or considerations about tislelizumab that haven't been discussed?
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
